Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX)

CAPS Rating: 2 out of 5

A biopharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of human viral and other infectious diseases with operations in the United States and Europe.


Player Avatar zzlangerhans (99.80) Submitted: 12/16/2007 9:55:35 PM : Underperform Start Price: $2.49 IDIX Score: -150.62

After the recent restructuring, it is now clear where this company stands. One HIV drug in phase I with no current plan for a phase II trial. One or two HCV drugs in preclinical development, with a history of one massive faceplant in HCV. Also a history of a very high burn rate which will obviously be reduced, but likely not as much as the company claims. 140M is simply too high of a market cap for this pipeline, and 70M would probably be more appropriate. As the company continues to bleed cash without significant progress through clinical trials in 2008, it will become clear that a dilutional financing is imminent.

Report this Post 3 Replies
Member Avatar BravoBevo (99.97) Submitted: 11/23/2009 11:43:22 AM
Recs: 0

Argh! I feel your frustration, bro. Isn't it such a pain when a pick has done what you've expected but because the timing of it you've got a neg score due to the market moving over the same period? And then we wait for both of them to catch up with each other to avoid a neg accuracy hit. In real life you'd be in the money, but here we wait and grimace when the stock price starts to back up on you.

Member Avatar geomedf (< 20) Submitted: 1/13/2012 4:10:56 AM
Recs: 0

At JPM health conference this week in SF, Ron Renaud Pres/CFO) stated a cash balance of $118.3 M as of 12/31/2011 which was 2x greater than Yahoo site, presented promising pipeline which he states positions IDIX in playing a major role in the evolving field of HCV therapy, and he stated that the cash burn of the past is now controlled and that there is more than enough cash to fund current pipeline well into 2013. link is IMHO, despite the Adam Feuerstein effect on this and other biotech stocks, this is a company worthy of a second look at this time. GF, M.D.

Member Avatar OklaBoston (67.60) Submitted: 4/4/2012 4:16:27 AM
Recs: 0

Some websurfing I just did due to a fit of insomnia reveals that no insider has payed more than $7.39/share for this in 2 years, and that most such purchases have been in the $2-$5 range. How can that be interpreted as even remotely bullish?

Featured Broker Partners